Cancer Research Cancer Epigenetics  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 69, 3249, April 15, 2009. Published Online First April 7, 2009;
doi: 10.1158/0008-5472.CAN-08-4710
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-08-4710v1
69/8/3249    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Northcott, P. A.
Right arrow Articles by Taylor, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Northcott, P. A.
Right arrow Articles by Taylor, M. D.

Priority Reports

The miR-17/92 Polycistron Is Up-regulated in Sonic Hedgehog–Driven Medulloblastomas and Induced by N-myc in Sonic Hedgehog–Treated Cerebellar Neural Precursors

Paul A. Northcott1, Africa Fernandez-L2, John P. Hagan3, David W. Ellison4, Wesia Grajkowska5, Yancey Gillespie6, Richard Grundy7, Timothy Van Meter8, James T. Rutka1, Carlo M. Croce3, Anna Marie Kenney2 and Michael D. Taylor1

1 Division of Neurosurgery, Arthur and Sonia Labatt Brain Tumour Research Centre, Program in Developmental and Stem Cell Biology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; 2 Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York; 3 Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University Medical Center, Columbus, Ohio; 4 Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee; 5 Department of Pathology, Children's Memorial Health Institute, Warsaw, Poland; 6 Department of Surgery, University of Alabama, Birmingham, Alabama; 7 University of Nottingham, Nottingham, United Kingdom; and 8 Department of Neurosurgery, Medical College of Virginia, Richmond, Virginia

Requests for reprints: Anna Marie Kenney, Memorial Sloan-Kettering, 1275 York Avenue, Box 446, New York, NY 10021. Phone: 646-888-2051; Fax: 646-422-0231; E-mail: kenneya{at}mskcc.org or Michael D. Taylor, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. Phone: 416-813-6427; Fax: 416-813-4975; E-mail: mdtaylor{at}sickkids.ca or Carlo M. Croce, Ohio State University, 1082 Biomedical Research Tower, 460 W. 12th Avenue, Columbus, OH 43210. Phone: 614-292-4930; Fax: 614-292-3558; E-mail: Carlo.croce@osumc.edu.

Key Words: medulloblastoma • miR-17/92 • microRNA • sonic hedgehog • cerebellar neural precursor • N-myc

Medulloblastoma is the most common malignant pediatric brain tumor, and mechanisms underlying its development are poorly understood. We identified recurrent amplification of the miR-17/92 polycistron proto-oncogene in 6% of pediatric medulloblastomas by high-resolution single-nucleotide polymorphism genotyping arrays and subsequent interphase fluorescence in situ hybridization on a human medulloblastoma tissue microarray. Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma. Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma. Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression. Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression. In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 expression. Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to increase proliferation and also enabled them to proliferate in the absence of Shh. We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas. [Cancer Res 2009;69(8):3249–55]




This article has been cited by other articles:


Home page
Cancer Res.Home page
N. V. Varlakhanova and P. S. Knoepfler
Acting Locally and Globally: Myc's Ever-Expanding Roles on Chromatin
Cancer Res., October 1, 2009; 69(19): 7487 - 7490.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.